Publication | Closed Access

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolMedicinePcsk9 InhibitionImmunologyPathologyHyperlipidemiaPharmacologyAtherosclerosisDyslipidemiaOxidative StressAmg 145